Healthcare / BiotechnologyNasdaqCM
$1.40
-0.01 (-0.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-12.9M · quality 38.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$178M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-35444.2%
↓Gross Margin
N/A
•Debt/Equity
8.77
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-18.4M · FCF $-12.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-18.4M | $-18.4M | $-11.9M | $-17.7M | $-15.4M |
| EBITDA | $-18.2M | $-18.2M | $-16.6M | $-17.1M | $-15.3M |
| EPS | -0.16 | -0.16 | -0.11 | -0.17 | -0.15 |
| Balance Sheet | |||||
| Debt/Equity | 8.77 | 8.77 | 0.03 | 0.04 | 0.02 |
| Current Ratio | 0.76 | 0.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.9M | $-12.9M | $-1.5M | $-15.7M | $-19.6M |
| Returns | |||||
| ROE | -35444.2% | -35444.2% | -301.4% | -319.6% | -78.7% |
| Valuation | |||||
| P/B | 3184.54 | 3184.54 | 19.78 | 11.29 | 3.27 |
| Growth & Yield | |||||
| EPS Growth | -45.5% | -45.5% | 35.3% | -13.3% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.11 → -0.16
Residual
+2.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.